OP0199 HAND OSTEOARTHRITIS PHENOTYPES AND THEIR ASSOCIATIONS WITH PAIN AND CHANGE IN PAIN

Background Hand osteoarthritis (OA) pain is characterized as heterogeneous and multifactorial. Different patterns may be explained by underlying phenotypes, which previously have not been explored. Objectives Using the biopsychosocial framework, we aimed to identify possible hand OA phenotypes explore associations with intensity change in during a four-year follow-up. Methods Latent class analysis was used determine classes of people OA, based on baseline examination (2016-17), followed posterior fit statistics. Biological, psychological, social domains were examined self-reported questionnaires, clinical assessment imaging. Central sensitization tested pressure thresholds (PPT; kg/cm 2 ) temporal summation (TS). Pain at follow-up (2019-21) Numeric Rating Scale (0-10) for overall bodily last 24 hours. Change calculated both measures. Differences variables measures assessed one-way ANOVAs chi-squared tests. The relations outcomes analysed linear regression. Results We identified five (Table 1). highest reported low severity but higher burden other factors (Class 5), whilst most hands lower extremities 4) approximately one point less (Figure Classes showed little there no significant difference (data shown). Significant differences found across all association pain. However, shown), except Class 5 (beta (95% CI); 1.13 (0.02, 2.25)). indicated comparison reference group 1) beta CI) 3.27 (2.32, 4.22) 3.08 (2.10, 4.07) 2.04 (1.02, 3.06) 2.74 (1.73, 3.76) follow-up, respectively. smaller when comparing 4 2.15 (1.27, 3.02) 2.20 3.13) baseline, 1.38 (0.46, 2.31) 1.66 (0.74, 2.58) 3 similar values (Hand pain: (95%) 2.24 (1.51, 2.97) 1.89 (1.12, 2.65)). Conclusion potential associated four years later. phenotype severity, more sensitization, comorbidities, psychological than severe extremities, reflecting discordance between experience. Table 1. Characteristics phenotypes. Data presented mean (SD) unless otherwise indicated. 1 N=93, 44% N=40, 19% N=38, 18% N=23, 11% N=19, 9% P-value Biological: Age 61 (6) 63 58 (5) (4) (7) <0.001 Sex (women), n (% 75 (80) 38 (95) 33 (87) 22 (96) 17 (90) 0.13 Radiographic 29.8 (16.2) 33.4 (16.9) 21.3 (15.2) 57.7 (12.6) 22.3 (18.7) Hips, knees feet 4.4 (3.1) 6.4 (3.3) 3.3 (2.1) 7.7 (4.1) 3.6 (3.6) PPT tibialis anterior 6.6 (2.7) (2.4) 4.7 5.5 4.6 TS 1.1 (1.2) 1.9 (1.7) 1.6 (1.5) 1.4 2.8 (1.8) BMI 24.8 (3.7) 30.2 (5.5) 26.0 (4.2) 26.9 28.7 Comorbidity 4.8 (2.6) 12.2 7.3 7.4 (3.2) 10.9 (4.5) Poor sleep, 47 (51) 34 (85) 37 (97) 19 (100) Psychological: HADS 4.1 (3.4) 7.1 8.3 6.2 (4.7) 19.4 ASES 75.9 (11.2) 68.3 (10.7) 61.6 71.3 (13.9) 47.2 (15.5) PCS (6.2) 12.5 (8.2) 12.4 (6.0) 10.5 (6.1) 21.1 (7.2) Social: University education, 69 (74) (60) 16 (42) 15 (65) 6 (32) Working, 72 (77) 8 (20) (63) 12 (55) SD=standard deviation Acknowledgements authors would like thank study participants, project coordinator Janicke Magnus user representative, Thalita Blanck, addition research assistants physicians who contributed Nor-Hand study. Disclosure Interests Elisabeth Mulrooney: None declared, Tuhina Neogi: Hanne Solveig Dagfinrud: Hilde Berner Hammer Speakers bureau: AbbVie, Novartis, Lilly, UCB; Honoraria lectures, Consultant of: Novartis; Advisory Board, Pernille Steen Pettersen: Tore K. Kvien Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi; Honorarium mee lectures , Biogen, Eli Gilead, Mylan, Pfizer, Sanofi. AbbVie: board Grant/research support from: BMS, Payment institution Karin Magnusson: Ida Haugen GSK; lecture, outside submitted work, Pfizer/Lily (ADVANCE); Paid institution.